Abstract
Original language | English |
---|---|
Pages (from-to) | 4743-4748 |
Number of pages | 6 |
Journal | FEBS Letters |
Volume | 581 |
Issue number | 24 |
DOIs | |
Publication status | Published - 2007 |
Fingerprint
Keywords
- Animals
- Carnitine O-Palmitoyltransferase
- Cell Line
- Fatty Acids
- Glucose
- Glycogen
- Insulin
- Muscle Fibers, Skeletal
- Muscle, Skeletal
- Oxidation-Reduction
- PPAR delta
- RNA-Binding Proteins
- Rats
- Sensitivity and Specificity
- Thiazoles
- Transcription Factors
Cite this
}
The PPARdelta agonist, GW501516, promotes fatty acid oxidation but has no direct effect on glucose utilisation or insulin sensitivity in rat L6 skeletal muscle cells. / Dimopoulos, Nikolaos; Watson, Maria; Green, Charlotte; Hundal, Harinder S.
In: FEBS Letters, Vol. 581, No. 24, 2007, p. 4743-4748.Research output: Contribution to journal › Article
TY - JOUR
T1 - The PPARdelta agonist, GW501516, promotes fatty acid oxidation but has no direct effect on glucose utilisation or insulin sensitivity in rat L6 skeletal muscle cells
AU - Dimopoulos, Nikolaos
AU - Watson, Maria
AU - Green, Charlotte
AU - Hundal, Harinder S
PY - 2007
Y1 - 2007
N2 - Peroxisome proliferator-activated receptor-delta (PPARdelta) activation enhances skeletal muscle fatty acid oxidation and improves whole body glucose homeostasis and insulin sensitivity. Recently, GW501516, a selective PPARdelta agonist, was reported to increase glucose uptake in human skeletal myotubes by an AMPK-dependent mechanism that may contribute to the improved glucose tolerance. Here, we demonstrate that whilst GW501516 increases expression of PGC-1alpha and CPT-1 and stimulates fatty-acid oxidation in L6 myotubes, it fails to enhance insulin sensitivity, AMPK activity or glucose uptake and storage. Our findings exclude sarcolemmal glucose transport as a potential target for the therapeutic action of PPARdelta agonists in skeletal muscle.
AB - Peroxisome proliferator-activated receptor-delta (PPARdelta) activation enhances skeletal muscle fatty acid oxidation and improves whole body glucose homeostasis and insulin sensitivity. Recently, GW501516, a selective PPARdelta agonist, was reported to increase glucose uptake in human skeletal myotubes by an AMPK-dependent mechanism that may contribute to the improved glucose tolerance. Here, we demonstrate that whilst GW501516 increases expression of PGC-1alpha and CPT-1 and stimulates fatty-acid oxidation in L6 myotubes, it fails to enhance insulin sensitivity, AMPK activity or glucose uptake and storage. Our findings exclude sarcolemmal glucose transport as a potential target for the therapeutic action of PPARdelta agonists in skeletal muscle.
KW - Animals
KW - Carnitine O-Palmitoyltransferase
KW - Cell Line
KW - Fatty Acids
KW - Glucose
KW - Glycogen
KW - Insulin
KW - Muscle Fibers, Skeletal
KW - Muscle, Skeletal
KW - Oxidation-Reduction
KW - PPAR delta
KW - RNA-Binding Proteins
KW - Rats
KW - Sensitivity and Specificity
KW - Thiazoles
KW - Transcription Factors
U2 - 10.1016/j.febslet.2007.08.072
DO - 10.1016/j.febslet.2007.08.072
M3 - Article
C2 - 17869249
VL - 581
SP - 4743
EP - 4748
JO - FEBS Letters
JF - FEBS Letters
SN - 0014-5793
IS - 24
ER -